Glaxo profits level despite diabetes drug claims

Drug maker GlaxoSmithKline today posted better than expected results, despite sales of its diabetes treatment Avandia falling more than 20% after health scares.

The company was rocked by claims in a US medical journal in May that Avandia increased the risk of heart attack, although Glaxo has strongly denied the accusations.